Project Grant R21DE033558
Award Date
9/15/24
Completion Date
9/14/26
Dollars Obligated
$429K
Federal Agency
National Institute of Dental and Craniofacial Research
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
William Penn Annex West, PA 19107, USA
Similar Awards
This $390,000 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to identify tumor antigen-specific T cells in oral squamous cell carcinoma (OSCC). The key products and services to be delivered include: Developing a high-throughput, single-cell co-culture system to isolate individual tumor-killing T cells and identify their T cell receptors (TCRs). Performing...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, provides $1,564,226 to Virginia Commonwealth University to investigate the role of FOSL1 super-enhancers in defining the functional properties of cisplatin-enriched cancer stem cells (CSCs) in head and neck squamous cell carcinoma (HNSCC). The research aims to validate FOSL1 super-enhancers as a target for overcoming...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $483,360 to the University of California, San Diego (UCSD) to conduct research aimed at identifying new precision therapies for oral cancer. The key focus is to exploit vulnerabilities in the EGFR/HER3/HER2 oncogenic signaling circuitry to disrupt immune evasive mechanisms and enhance the activity of anti-PD-1...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to advance understanding of the mechanisms behind radiotherapy resistance in head and neck squamous cell carcinoma (HNSCC). The $320,000 award, effective from July 15, 2025 to July 14, 2027, supports research conducted by Baylor College of Medicine to: Investigate how the KEAP1/NRF2 signaling pathway and the tumor immune...
This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...
This federal Project Grant award, titled "Engineering Oral Tumor Microcirculation: Blood and Lymphatic Capillary Network-Enabled Human Oral Tumor Microenvironment Chips for Preclinical Research", is funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The $421,625 award, effective from July 1, 2025 to June 30, 2027, will support the development of advanced tumor microenvironment chips...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,403,398 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on precision imaging approaches for understanding the spatial regulators of the hybrid epithelial/mesenchymal state in head and neck cancer. The project aims to utilize advanced imaging techniques to investigate how the hybrid...
This $799,270 federal project grant awarded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) will support the development of a novel class of anticancer drugs called 1,3-thioureas for the treatment of oral squamous cell carcinoma (OSCC). The grant recipient, Keraceuticals, Inc., will focus on formulating the lead compound CIDD99 for oral and/or intravenous administration, evaluating its efficacy in mouse...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $204,688 to The Johns Hopkins University from May 1, 2025 to April 30, 2027. The project aims to evaluate and compare the ability of Salmonella-derived nanoparticles (SAL-9RE7 and SOMV-9RE7) to mediate tumor control and induce HPV E7-specific T cell immunity. It will also evaluate the potency of a combination treatment...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $808,264 Project Grant under the Oral Diseases and Disorders Research (CFDA 93.121) federal grant program to The Medical University of South Carolina. The grant aims to elucidate the mechanisms underlying filopodia-mediated intracellular uptake of a cell-penetrating peptide (RD3AD) complex carrying small interfering RNAs (siRNAs), and to determine its ability to target and deliver siRNAs to migrating/invading oral...